3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Gastrointestinal
1
Endocrine
1
CNS
1
Conditions
Ovarian Neoplasms
2
Multiple Myeloma
2
Hematologic Neoplasms
2
Glioma
2
Colorectal Neoplasms
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Neoplasms by Site
1
Neoplasms by Histologic Type
1
Neoplasms
1
Melanoma
1
Lymphoproliferative Disorders
1
Lymphoma
1
Lung Neoplasms
1
Laryngeal Neoplasms
1
Histiocytosis, Langerhans-Cell
1
Gastrointestinal Neoplasms
1
Esophageal Neoplasms
1
Erdheim-Chester Disease
1
Endometrial Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Interventions
Fulvestrant
3
cobimetinib
2
anlotinib
2
Bevacizumab
2
trametinib
1
selinexor
1
ribociclib
1
relacorilant
1
palbociclib
1
osimertinib
1
olaparib
1
niraparib
1
nintedanib
1
exemestane
1
enzalutamide
1
dabrafenib
1
atezolizumab
1
alectinib
1
abemaciclib
1
Watchful Waiting
1
Vemurafenib
1
Transurethral Resection of Prostate
1
Trabectedin
1
Tamoxifen
1
STX-478
1
Pregnancy Tests
1
Pemetrexed
1
Metformin
1
Letrozole
1
Imlunestrant
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Site
×
dabrafenib
×
Gynecologic
×
Clear all
NCT07440290
2026-02-27
DETERMINE
Cancer Research UK
Phase 2/3
Not yet recruiting
30 enrolled